Hilar cholangiocarcinoma
Conditions
Interventions
S-1 alone:S1 was used alone twice daily on days 28 days, followed by a 14-day rest period
Gemcitable+5FU:Gemcitabine 1000 mg/m2 on day 1 and 15 for 4 weeks, combined with 5FU injected intravenously on day 1 and 15 for weeks at a dose of 750mg/person
gemcitable+S1:Gemcitabine intravenously at 1000 mg/m2 on days 1 and 15 and S-1 oral twice daily for 2 weeks followed by a 2-week rest between each 4-week cycle
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Age
34 Years to 71 Years
Inclusion criteria
Inclusion criteria: 1. Hilar cholangiocarcinoma diagnosed by pathological examination or typical radiographic findings; 2. Unresectable locally advanced or metastatic disease; 3. No prior treatment for hilar cholangiocarcinoma includign surgery or radiation therapy; 4. Age>18 years; 5. To be able to oral intake the chemotherapy drugs.
Exclusion criteria
Exclusion criteria: 1. Severe complications, such as active infection, cardiac or renal disease, marked pleural effusion, or ascites; 2. Active gastrointeatinal bleeing; 3. Severe drug hypersensitivity; 4. Active concomitant malignancy; and 5. Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Leukocyte; | — |
Countries
China
Contacts
Public ContactGuangwen Zhou
Shanghai Jiao Tong University School of Medicine
Outcome results
None listed